Press Releases

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Lobe Sciences Ltd. (“Lobe” or the “Company”) (OTCQB: LOBEF) (CSE: LOBE), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases and Clearway Global, LLC (“Clearway”), a wholly owned subsidiary of Sancilio & Company (“Sancilio”), a pharmaceutical services company focused on value creation strategies, are pleased to announce a change in control of the Company and... (continue reading...)

Insurance coverage includes accident, sickness and critical illness insurance plans with optional disability income, optional hospital indemnity, physician and Urgent Care visits, and emergency room benefits

SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- Flex Benefits Insurance Services announces its official company launch. The company offers proprietary product solutions that help individuals and families obtain insurance protections to combat ever-soaring high... (continue reading...)

NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- EdgarAgents (EA), a leader in transaction filings and the fastest-growing SEC filing agent and financial printer, reports successful test filings of the updated Form N-CSR containing iXBRL tagged Tailored Shareholder Reports (TSR). EA confidently offers a true end-to-end TSR Solution ahead of the SEC's compliance deadline of July 24, 2024. EA showcases their dedication to innovation,  enabling customer service excellence... (continue reading...)

CINCINNATI, May 21, 2024 (GLOBE NEWSWIRE) -- Ultimus Fund Solutions® (Ultimus®), a leading independent provider of full-service, technology-enhanced fund administration, accounting, and investor solutions, is proud to announce that current client Kingsview Wealth Management, LLC (“Kingsview”) once more turned to Ultimus to assist in four new ETF launches. Ultimus first collaborated with Kingsview in March of 2021 to support the launch of the three initial... (continue reading...)

MONTREAL--(BUSINESS WIRE)-- AmorChem II Fund L.P. (''AmorChem'') is delighted to announce that its RNA Zipcode delivery program has been acquired by Kodikaz Therapeutic Solutions, Inc. (''Kodikaz''), a New York City biotech focused on targeted delivery of cancer therapeutics. The RNA Zipcode program was the first university-based investment of AmorChem’s second fund and was developed by Professors Eric Lécuyer (Montreal Clinical Research Institute), Mathieu... (continue reading...)